Asia Pacific Oncology Based Molecular Diagnostics Market Size, Share & Trends Analysis Report By Type (Breast Cancer, Lung Cancer), By Product (Instruments, Reagents), By Technology, By Region, And Segment Forecasts, 2024 - 2030

Table of Contents

Chapter 1. Methodology and Scope
                      1.1. Market Segmentation & Scope
                      1.2. Segment Definitions
                          1.2.1. Type
                          1.2.2. Technology
                          1.2.3. Product
                          1.2.4. Country scope
                          1.2.5. Estimates and forecasts timeline
                      1.3. Research Methodology
                      1.4. Information Procurement
                          1.4.1. Purchased database
                          1.4.2. GVR’s internal database
                          1.4.3. Secondary sources
                          1.4.4. Primary research
                          1.4.5. Details of primary research
                              1.4.5.1. Data for primary interviews in Asia Pacific
                      1.5. Information or Data Analysis
                          1.5.1. Data analysis models
                      1.6. Market Formulation & Validation
                      1.7. Model Details
                          1.7.1. Commodity flow analysis (Model 1)
                          1.7.2. Approach 1: Commodity flow approach
                      1.8. List of Secondary Sources
                      1.9. List of Primary Sources
                      1.10. Objectives
Chapter 2. Executive Summary
                      2.1. Market Outlook
                      2.2. Segment Outlook
                          2.2.1. Type outlook
                          2.2.2. Technology outlook
                          2.2.3. Product outlook
                          2.2.4. Country outlook
                      2.3. Competitive Insights
Chapter 3. Asia Pacific Oncology Based Molecular Diagnostics Market Variables, Trends & Scope
                      3.1. Market Lineage Outlook
                          3.1.1. Parent market outlook
                          3.1.2. Related/ancillary market outlook
                      3.2. Market Dynamics
                          3.2.1. Market Driver Analysis
                          3.2.2. Market Restraint Analysis
                      3.3. Asia Pacific Oncology Based Molecular Diagnostics Market Analysis Tools
                          3.3.1. Industry Analysis - Porter’s
                              3.3.1.1. Supplier power
                              3.3.1.2. Buyer power
                              3.3.1.3. Substitution threat
                              3.3.1.4. Threat of new entrant
                              3.3.1.5. Competitive rivalry
                          3.3.2. PESTEL Analysis
                              3.3.2.1. Political landscape
                              3.3.2.2. Technological landscape
                              3.3.2.3. Economic landscape
Chapter 4. Asia Pacific Oncology Based Molecular Diagnostics Market: Type Estimates & Trend Analysis
                      4.1. Asia Pacific Oncology Based Molecular Diagnostics Market: Type Dashboard
                      4.2. Asia Pacific Oncology Based Molecular Diagnostics Market: Type Movement Analysis
                      4.3. Asia Pacific Oncology Based Molecular Diagnostics Market Estimates and Forecasts, By Type, Revenue (USD Million)
                      4.4. Breast Cancer
                          4.4.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
                      4.5. Prostate Cancer
                          4.5.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
                      4.6. Colorectal Cancer
                          4.6.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
                      4.7. Cervical Cancer
                          4.7.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
                      4.8. Liver Cancer
                          4.8.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
                      4.9. Lung Cancer
                          4.9.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
                      4.10. Blood Cancer
                          4.10.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
                      4.11. Kidney Cancer
                          4.11.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
                      4.12. Other Cancer
                          4.12.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
Chapter 5. Asia Pacific Oncology Based Molecular Diagnostics Market: Technology Estimates & Trend Analysis
                      5.1. Asia Pacific Oncology Based Molecular Diagnostics Market: Technology Dashboard
                      5.2. Asia Pacific Oncology Based Molecular Diagnostics Market: Technology Movement Analysis
                      5.3. Asia Pacific Oncology Based Molecular Diagnostics Market Estimates and Forecasts, By Technology, Revenue (USD Million)
                      5.4. PCR
                          5.4.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
                      5.5. INAAT
                          5.5.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
                      5.6. Mass spectrometry
                          5.6.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
                      5.7. Sequencing
                          5.7.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
                      5.8. TMA
                          5.8.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
                      5.9. others
                          5.9.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
Chapter 6. Asia Pacific Oncology Based Molecular Diagnostics Market: Product Estimates & Trend Analysis
                      6.1. Asia Pacific Oncology Based Molecular Diagnostics Market: Product Dashboard
                      6.2. Asia Pacific Oncology Based Molecular Diagnostics Market: Product Movement Analysis
                      6.3. Asia Pacific Oncology Based Molecular Diagnostics Market Estimates and Forecasts, By Product, Revenue (USD Million)
                      6.4. Instruments
                          6.4.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
                      6.5. Reagents
                          6.5.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
                      6.6. Others
                          6.6.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
Chapter 7. Asia Pacific Oncology Based Molecular Diagnostics Market: Country Estimates & Trend Analysis
                      7.1. Country Market Share Analysis, 2023 & 2030
                      7.2. Country Market Dashboard
                      7.3. Country Market Snapshot
                      7.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
                      7.5. Asia Pacific
                          7.5.1. Japan
                              7.5.1.1. Key country dynamics
                              7.5.1.2. Regulatory framework/ reimbursement structure
                              7.5.1.3. Competitive scenario
                              7.5.1.4. Japan market estimates and forecasts, 2018 - 2030 (USD Million)
                          7.5.2. China
                              7.5.2.1. Key country dynamics
                              7.5.2.2. Regulatory framework/ reimbursement structure
                              7.5.2.3. Competitive scenario
                              7.5.2.4. China market estimates and forecasts, 2018 - 2030 (USD Million)
                          7.5.3. India
                              7.5.3.1. Key country dynamics
                              7.5.3.2. Regulatory framework/ reimbursement structure
                              7.5.3.3. Competitive scenario
                              7.5.3.4. India market estimates and forecasts, 2018 - 2030 (USD Million)
                          7.5.4. Australia
                              7.5.4.1. Key country dynamics
                              7.5.4.2. Regulatory framework/ reimbursement structure
                              7.5.4.3. Competitive scenario
                              7.5.4.4. Australia market estimates and forecasts, 2018 - 2030 (USD Million)
                          7.5.5. New Zealand
                              7.5.5.1. Key country dynamics
                              7.5.5.2. Regulatory framework/ reimbursement structure
                              7.5.5.3. Competitive scenario
                              7.5.5.4. New Zealand market estimates and forecasts, 2018 - 2030 (USD Million)
Chapter 8. Competitive Landscape
                      8.1. Recent Developments & Impact Analysis, By Key Market Participants
                      8.2. Company/Competition Categorization
                      8.3. Vendor Landscape
                          8.3.1. List of key distributors and channel partners
                          8.3.2. Key customers
                          8.3.3. Key company market share analysis, 2023
                      8.4. Company Profiles
                          8.4.1. Abbott Laboratories
                              8.4.1.1. Company overview
                              8.4.1.2. Financial performance
                              8.4.1.3. Product benchmarking
                              8.4.1.4. Strategic initiatives
                          8.4.2. Agilent Technologies Inc
                              8.4.2.1. Company overview
                              8.4.2.2. Financial performance
                              8.4.2.3. Product benchmarking
                              8.4.2.4. Strategic initiatives
                          8.4.3. bioMerieux SA
                              8.4.3.1. Company overview
                              8.4.3.2. Financial performance
                              8.4.3.3. Product benchmarking
                              8.4.3.4. Strategic initiatives
                          8.4.4. Danaher
                              8.4.4.1. Company overview
                              8.4.4.2. Financial performance
                              8.4.4.3. Product benchmarking
                              8.4.4.4. Strategic initiatives
                         8.4.5. F. Hoffmann-La Roche AG
                              8.4.5.1. Company overview
                              8.4.5.2. Financial performance
                              8.4.5.3. Product benchmarking
                              8.4.5.4. Strategic initiatives
                          8.4.6. Illumina Inc
                              8.4.6.1. Company overview
                              8.4.6.2. Financial performance
                              8.4.6.3. Product benchmarking
                              8.4.6.4. Strategic initiatives
                          8.4.7. Novartis AG
                              8.4.7.1. Company overview
                              8.4.7.2. Financial performance
                              8.4.7.3. Product benchmarking
                              8.4.7.4. Strategic initiatives
                          8.4.8. Qiagen NV
                              8.4.8.1. Company overview
                              8.4.8.2. Financial performance
                              8.4.8.3. Product benchmarking
                              8.4.8.4. Strategic initiatives
                          8.4.9. Siemens Healthineers AG
                              8.4.9.1. Company overview
                              8.4.9.2. Financial performance
                              8.4.9.3. Product benchmarking
                              8.4.9.4. Strategic initiatives
                          8.4.10. TBG Diagnostics Limited
                              8.4.10.1. Company overview
                              8.4.10.2. Financial performance
                              8.4.10.3. Product benchmarking
                              8.4.10.4. Strategic initiatives
                          8.4.11. Thermo Fisher Scientific Inc
                              8.4.11.1. Company overview
                              8.4.11.2. Financial performance
                              8.4.11.3. Product benchmarking
                              8.4.11.4. Strategic initiatives
                          8.4.12. Sysmex
                              8.4.12.1. Company overview
                              8.4.12.2. Financial performance
                              8.4.12.3. Product benchmarking
                              8.4.12.4. Strategic initiatives

List of Tables

Table 1 List of abbreviations
Table 2 Asia Pacific oncology based molecular diagnostics market, 2018 - 2030 (USD Million)
Table 3 Asia Pacific oncology based molecular diagnostics market, by type, 2018 - 2030 (USD Million)
Table 4 Asia Pacific oncology based molecular diagnostics market, by technology, 2018 - 2030 (USD Million)
Table 5 Asia Pacific oncology based molecular diagnostics market, by product, 2018 - 2030 (USD Million)
Table 6 China oncology based molecular diagnostics, by type, 2018 - 2030 (USD Million)
Table 7 China oncology based molecular diagnostics, by technology, 2018 - 2030 (USD Million)
Table 8 China oncology based molecular diagnostics, by product, 2018 - 2030 (USD Million)
Table 9 Japan oncology based molecular diagnostics market, by type, 2018 - 2030 (USD Million)
Table 10 Japan oncology based molecular diagnostics market, by technology, 2018 - 2030 (USD Million)
Table 11 Japan oncology based molecular diagnostics market, by product, 2018 - 2030 (USD Million)
Table 12 India oncology based molecular diagnostics market, by type, 2018 - 2030 (USD Million)
Table 13 India oncology based molecular diagnostics market, by technology, 2018 - 2030 (USD Million)
Table 14 India oncology based molecular diagnostics market, by product, 2018 - 2030 (USD Million)
Table 15 Australia oncology based molecular diagnostics market, by type, 2018 - 2030 (USD Million)
Table 16 Australia oncology based molecular diagnostics market, by technology, 2018 - 2030 (USD Million)
Table 17 Australia oncology based molecular diagnostics market, by product, 2018 - 2030 (USD Million)
Table 18 New Zealand oncology based molecular diagnostics market, by type, 2018 - 2030 (USD Million)
Table 19 New Zealand oncology based molecular diagnostics market, by technology, 2018 - 2030 (USD Million)
Table 20 New Zealand oncology based molecular diagnostics market, by product, 2018 - 2030 (USD Million)

List of Figures

Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Primary interviews in APAC
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 QFD modeling for market share assessment
Fig. 8 Market formulation & validation
Fig. 9 Asia Pacific oncology based molecular diagnostics market: market outlook
Fig. 10 Asia Pacific oncology based molecular diagnostics competitive insights
Fig. 11 Parent market outlook
Fig. 12 Related/ancillary market outlook
Fig. 13 Penetration and growth prospect mapping
Fig. 14 Industry value chain analysis
Fig. 15 Asia Pacific oncology based molecular diagnostics market driver impact
Fig. 16 Asia Pacific oncology based molecular diagnostics market restraint impact
Fig. 17 Asia Pacific oncology based molecular diagnostics market strategic initiatives analysis
Fig. 18 Asia Pacific oncology based molecular diagnostics market: Type movement analysis
Fig. 19 Asia Pacific oncology based molecular diagnostics market: Type outlook and key takeaways
Fig. 20 Breast cancer market estimates and forecast, 2018 - 2030
Fig. 21 Prostate cancer market estimates and forecast, 2018 - 2030
Fig. 22 Colorectal cancer market estimates and forecast, 2018 - 2030
Fig. 23 Cervical cancer market estimates and forecast, 2018 - 2030
Fig. 24 Liver cancer market estimates and forecast, 2018 - 2030
Fig. 25 Lung cancer market estimates and forecast, 2018 - 2030
Fig. 26 Blood cancer market estimates and forecast, 2018 - 2030
Fig. 27 Kidney cancer market estimates and forecast, 2018 - 2030
Fig. 28 Other cancer market estimates and forecast, 2018 - 2030
Fig. 29 Asia Pacific oncology based molecular diagnostics market: Technology movement Analysis
Fig. 30 Asia Pacific oncology based molecular diagnostics market: Technology outlook and key takeaways
Fig. 31 PCR market estimates and forecasts, 2018 - 2030
Fig. 32 In Situ Hybridization market estimates and forecasts, 2018 - 2030
Fig. 33 INAAT market estimates and forecasts, 2018 - 2030
Fig. 34 Chips and microarrays market estimates and forecasts, 2018 - 2030
Fig. 35 Mass spectrometry market estimates and forecasts, 2018 - 2030
Fig. 36 Sequencing market estimates and forecasts, 2018 - 2030
Fig. 37 TMA market estimates and forecasts, 2018 - 2030
Fig. 38 Others market estimates and forecasts, 2018 - 2030
Fig. 39 Asia Pacific oncology based molecular diagnostics market: product movement analysis
Fig. 40 Asia Pacific oncology based molecular diagnostics market: product outlook and key takeaways
Fig. 41 Instruments market estimates and forecasts, 2018 - 2030
Fig. 42 Reagents market estimates and forecasts,2018 - 2030
Fig. 43 Others market estimates and forecasts, 2018 - 2030
Fig. 44 Asia Pacific oncology based molecular diagnostics market: Country movement analysis
Fig. 45 Asia Pacific oncology based molecular diagnostics market: Country outlook and key takeaways
Fig. 46 Asia Pacific oncology based molecular diagnostics market share and leading players
Fig. 47 Asia Pacific SWOT
Fig. 48 Asia Pacific
Fig. 49 Asia Pacific market estimates and forecasts, 2018 - 2030
Fig. 50 China
Fig. 51 China market estimates and forecasts, 2018 - 2030
Fig. 52 Japan
Fig. 53 Japan market estimates and forecasts, 2018 - 2030
Fig. 54 India
Fig. 55 India market estimates and forecasts, 2018 - 2030
Fig. 56 Australia
Fig. 57 Australia market estimates and forecasts, 2018 - 2030
Fig. 58 New Zealand
Fig. 59 New Zealand market estimates and forecasts, 2018 - 2030
Fig. 60 Market share of key market players- Asia Pacific oncology based molecular diagnostics market